Literature DB >> 3857071

The myelodysplastic syndromes: different evolution patterns based on sequential morphological and cytogenetic investigations.

G Tricot, M A Boogaerts, C De Wolf-Peeters, H Van den Berghe, R L Verwilghen.   

Abstract

Serial morphological and cytogenetic investigations were performed in 46 patients with the myelodysplastic syndrome (MDS). Twenty-one patients (45.5%) progressed to AML (greater than 30% blasts in bone marrow smears). Based on sequential determinations of percentages of bone marrow blasts, three patterns of evolution were observed in MDS. Patients with evolution pattern A (48%) had an apparently stable disease with minimal or no increase in bone marrow blasts. Exceptionally they developed new or additional chromosomal anomalies during the course of their disease. Cases in this group, who showed no abnormal localization of immature myeloid precursors (ALIP) at time of diagnosis experienced prolonged survival (median: 43 months), while ALIP positive patients had shorter survival times (median: 14 months), with high probability of early death from infections and/or bleeding problems. Patients with evolution pattern B (28%) initially had a morphologically stable disease, comparable to cases with evolution pattern A, but showed an abrupt shift from MDS to AML. Most of these patients (82%) were ALIP positive and a substantial proportion (46%) showed karyotype anomalies at diagnosis. The abrupt shift to AML in these patients was frequently (61.5%) associated with additional cytogenetic anomalies. Patients with evolution pattern C (24%) showed a gradual increase in bone marrow blasts. The majority of these cases (8/11) ultimately developed acute myeloid leukaemia (gradual progression to AML), whereas some patients (3/11) died from infections and/or haemorrhagic complications before they had reached the level of clinical AML. All of these patients were ALIP positive at diagnosis and no additional cytogenetic alterations occurred during evolution. Acquisition of new karyotypic anomalies during the course of MDS was almost invariably associated with abrupt shift to AML. From this retrospective study we conclude that evolution in MDS shows two important aspects, which seem to be preponderant in determining the course and outcome of the disease: one is the proliferative capacity and resulting growth advantage of the neoplastic clone over normal haematopoiesis, as measured by increasing percentages of bone marrow blasts in sequential aspirates; the other one is instability of the clone. Unstable clones have a high propensity to further intraclonal changes; they are expressed morphologically by the abrupt increase in bone marrow blasts and cytogenetically by the acquisition of new or additional karyotype anomalies.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1985        PMID: 3857071     DOI: 10.1111/j.1365-2141.1985.tb07361.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

Review 1.  Myelodysplastic syndromes.

Authors:  D C Doll; A F List
Journal:  West J Med       Date:  1989-08

2.  Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.

Authors:  M Werner; H Maschek; V Kaloutsi; H Choritz; A Georgii
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 3.  Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature.

Authors:  Norihide Sato; Tomonori Nakazato; Masahiro Kizaki; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 4.  Myelodysplastic syndromes: their history, evolution and relation to acute myeloid leukaemia.

Authors:  D M Layton; G J Mufti
Journal:  Blut       Date:  1986-12

Review 5.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

6.  The significance of pancytopenia in miliary tuberculosis.

Authors:  B J Hunt; V Andrews; K W Pettingale
Journal:  Postgrad Med J       Date:  1987-09       Impact factor: 2.401

7.  Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.

Authors:  Elias Jabbour; Koichi Takahashi; Xuemei Wang; A Megan Cornelison; Lynne Abruzzo; Tapan Kadia; Gautam Borthakur; Zeev Estrov; Susan O'Brien; Mar Mallo; William Wierda; Sherry Pierce; Yue Wei; Francisco Sole; Rui Chen; Hagop Kantarjian; Guillermo Garcia-Manero
Journal:  Am J Hematol       Date:  2013-07-23       Impact factor: 10.047

8.  Myelodysplastic syndromes in childhood: description of seven cases.

Authors:  A Vitale; A M Testi; M L Moleti; M Vignetti; W Arcese; S Fenu; M Cedrone; L De Felice; S Amadori; F Mandelli
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

9.  The prognostic significance of cytological, histological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. A follow up study.

Authors:  G Kerndrup; K Bendix-Hansen; B Pedersen
Journal:  Blut       Date:  1987-04

Review 10.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.